California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.

We recently published an article titled Jim Cramer Discusses These 12 Stocks & Says Late Selloffs Are Deliberate. In this ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug ...

As Heart Month reminds us of the critical need to protect our cardiovascular and metabolic (CVM) health, Novo Nordisk ...